Atorvastatin
- PDF / 169,573 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 54 Downloads / 161 Views
1 S
Atorvastatin Rhabdomyolysis: case report
A 62-year-old man developed rhabdomyolysis during treatment with atorvastatin for ST-segment elevation myocardial infarction (STEMI) [route and duration of treatment to reaction onset not stated]. The man presented with pain and generalised muscle weakness. One month prior, he had undergone percutaneous coronary intervention for STEMI. Laboratory parameters revealed an increase in levels of AST, ALT, creatine kinase and myoglobin. Furthermore, the assessment after calculation of glomerular filtration rate suggested deteriorated renal function. His diagnostic findings confirmed rhabdomyolysis. The man underwent massive hydration. The blood pooling images obtained from bone scintigraphy employing Tc-99m hydroxymethane diphosphonate on hospital day 5 showed an increased radioisotope uptake by both upper extremities and the thigh muscles. He had been receiving atorvastatin 40 mg/day after STEMI. The treatment with atorvastatin was discontinued. Subsequently, the levels of creatine kinase and myoglobin decreased gradually. He was discharged without muscular symptoms on day 20 of admission. However, the levels of creatinine kinase and myoglobin were still above the baseline. His renal function and the AST/ALT levels returned to normal. He was prescribed pitavastatin and ezetimibe to substitute the high-intensity statin. Kim MC, et al. Image of statin-induced rhabdomyolysis. Korean Circulation Journal 50: E59, No. 8, Aug 2020. Available from: URL: http://doi.org/10.4070/ KCJ.2019.0410
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803502971
Reactions 26 Sep 2020 No. 1823
Data Loading...
